Thursday, February 1, 2018

Big Pharma Muscles Their Way Into New Mexico’s Roundhouse


This is a gateway drug bill for big pharma 
into the New Mexico Medical Cannabis Program.

In the 30 Day Session at the Roundhouse, both Senate Bill 249 and House Bill 139 “Marijuana Derivative Drug Exemptions” is a direct result of a foreign pharmaceutical company, GW Pharmaceuticals, using their vast wealth to pay lobbyist to bring this bill forward. 

This legislation is bad news for the state’s medical cannabis community. This legislation makes it way to easy for George Soros and German Bayer AG who have a signed an agreement with GW Pharmaceuticals for joint research on a cannabis-based extract. Bayer AG agreed to an exchange of technology with Monsanto, thus Monsanto has discreet access to the work of the cannabis plant and its genetic modification. House Bill 139 is sponsored by Rep. Youngblood and Rep. Deborah Armstrong.

The U.S. Food and Drug Administration (FDA) is aware that cannabis and cannabis-derived products are being used for a number of medical conditions, such as AIDS wasting syndrome, epilepsy, neuropathic pain, treatment of spasticity associated with multiple sclerosis, and cancer and chemotherapy-induced nausea.

Despite this fact, the FDA has not yet approved a marketing application for a drug product containing or derived from the whole cannabis plant. It has, however, approved three cannabinoid-based medicines derived from isolated synthetics: Marinol, Syndros, and Cesamet. And they want to treat opioid addiction with these fake cannabis drugs.

Last year, the FDA approved a new liquid formulation of dronabinol. The new version of the drug is made by DPT Lakewood LLC for Insys Therapeutics and is marketed under the brand name Syndros. Not surprisingly, Insys Therapeutics contributed at least $500,000 to Arizona’s successful anti-cannabis legalization efforts. Insys is also the company responsible for Subsys, a fentanyl-based medicine and a super opioid 50 times stronger than heroin.It has been suggested that Syndros could generate peak annual sales of up to $400 million.
Read more here about the other drugs this bill will let into New Mexico here: http://www.cannabisnewsjournal.co/2018/01/three-different-cannabinoid-based.html





Currently a mother in the state’s medical cannabis program who uses a product like Haleigh’s Hope will spend $1800 per year according to the Flowering Hope Foundation.

The Denver Post post reports the Epidiolex will cost $2,500-$5,000 per month, yes that is correct per month.

Who is going to explain to these people using medical cannabis that they now have to pay near $50,000 per year for a synthetic cannabis prescription that is not going to be as effective in treatment?

As reported by Motherboard, the drug industry is now pushing for legislation that would make CBD oil illegal — by turning it into a drug.

“Not surprisingly, GW Pharmaceuticals has just such a drug in the pipeline. Epidiolex, a ‘proprietary oral solution of pure plant-derived cannabidiol,’ has already been given to epileptic children in the U.S. as part of a federal investigative study documented recently in the New England Journal of Medicine.” Motherboard writes. Epidiolex is currently under FDA review for approval.

During 2017 the Medical Cannabis Advisory Board meet twice, once in April and once more in November. There was not one state legislator in attendance for either one in 2017.

Interestingly, while medical cannabis is typically well-tolerated, with few side effects, a whopping 93 percent of children in the CBD group — as well as 75 percent of those in the placebo group — suffered adverse events in this trial.

Eighty-four percent of adverse events in the treatment group were deemed mild or moderate, and included vomiting, fatigue, fever, upper respiratory tract infection, decreased appetite, convulsions, lethargy, drowsiness and diarrhea. Eight patients in the treatment group withdrew from the study due to side effects.

It’s possible that “pharmaceutical strength” CBD might be too pure, hence the high rate of side effects. Regardless, there’s a significant difference in cost between a CBD drug and natural CBD oil, which in and of itself is of great concern for many patients and their families who now worry Big Pharma is trying to take over the cannabis industry.
(Source: The randomized, double-blind, placebo-controlled study published in The New England Journal of Medicine in May 2017 & Dr. Mercola.)

The purpose of the Lynn and Erin Compassionate Use Act is to allow the beneficial use of medical cannabis and this is Not being fulfilled.

Today there is less than ⅓ of a medical cannabis plant available per medical cannabis patient. This does not provide for “adequate supply” as required by the LECUA law.



Lastly could we also please stop using the Racist term “Marijuana” in state legislation as “Cannabis” is the scientific term and we do live in a minority-majority state, it’s already bad enough the state constitution refers to the Governor’s Office as a Male only role…

Article: “Marijuana: is it time to stop using a word with racist roots?”

https://www.theguardian.com/society/2018/jan/29/marijuana-name-cannabis-racism

1 comment: